Int J Clin Exp Pathol 2015;8(8):9580-9585 www.ijcep.com /ISSN:1936-2625/IJCEP0010205 Original Article Role of IL-10 gene polymorphisms on the susceptibility for esophageal cancer and its association with environmental factors Yingtao Yang 1,2, Xianen Fa 1 1 The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 2 The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China Received May 14, 2015; Accepted June 26, 2015; Epub August 1, 2015; Published August 15, 2015 Abstract: We conducted a hospital-based case-control study to investigate the association of three common SNPs (-1082G/A rs1800896, -819T/C rs1800871, and -592A/C rs1800872) of IL-10 gene polymorphisms with the susceptibility to esophageal cancer in a Chinese population. 246 patients with pathologically proven esophageal cancer and 492 healthy control subjects were collected in our study. Genotyping of IL-10-1082G/A rs1800896, -819T/C rs1800871, and -592A/C rs1800872 was performed using the Sequenom MassARRAY platform (Sequenom; San Diego, CA). Unconditional logistic regression analyses showed that subjects carrying the AA genotype and GA+AA genotype of IL-10-1082G/A rs1800896 were associated with an increased risk of esophageal cancer, and the adjusted ORs (95% CI) were 2.19 (1.31-3.64) and 1.44 (1.05-1.99), respectively. However, we did not find significant association of IL-10-819T/C rs1800871 and -592A/C rs1800872 with the development of esophageal cancer. By stratification analysis, we found that IL-10-1082G/A rs1800896 polymorphism has no significant association with smoking, drinking and family history of cancer in the first relatives in esophageal cancer risk (P>0.05). In conclusion, IL-10-1082G/A rs1800896 genetic variation may be employed as candidate biomarkers for the prediction of susceptibility in esophageal cancer. Keywords: IL-10, polymorphism, esophageal cancer, environmental factors Introduction Esophageal cancer is the eighth most common causes of cancer-related mortality worldwide, with an estimated 456,000 new esophageal cancer cases in 2012 [1]. There were two different forms of esophageal cancer, including esophageal squamous cell carcinoma and esophageal adenocarcinoma. In China, it is estimated that 223,306 new esophageal cancer cases were diagnosed and 197,472 died in 2012, and the incidence was ranked fifth and the mortality was ranked fourth of all cancers in Chinese population [1]. Around 80% of the cases worldwide occur in less developed regions. More than half of the esophageal cancer cases were diagnosed in China [2]. The development of esophageal carcinoma is a complex, multistep and multifactorial process, and many environmental and genetic factors are involved in the development of this cancer. Previous studies have reported that tobacco smoking, hot beverage intake and alcohol drinking contribute to the development of esophageal cancer [3, 4]. However, not all these prostate cancer patients would develop esophageal cancer even when they have been exposed to similar risk factor, which suggests that genetic variations could influence the development of esophageal cancer. Several previous studies have reported that genetic polymorphisms play an important role in the development of esophageal cancer, such as XRCC1, XRCC5, XRCC6, ALDH2, and CYP1A1 [5-8]. Chronic inflammation in esophageal tissues could contribute to the susceptibility of esophageal cancer, and thus multiple genes involved in the inflammatory pathways could play an important role in the development of this cancer. Interleukin-10 (IL-10) is an immunoregulatory cytokine, which is produced by Th2 cells, regulatory T cells, and monocytes/macrophages. The encoding gene of IL-10 is located on chromosome 1 (1q31-1q32). IL-10 is an anti-inflam-
Table 1. Primers and PCR products of IL-10-1082G/A rs1800896, -819T/C rs1800871, and -592A/C rs1800872 IL-10 SNP Primers Restriction enzyme PCR products -1082G/A rs1800896 5 -CTACTAAGGCTTCTTTGGGAG-3 5 -ACTACTAAGGCTTCTTTGGGAA-3-819T/C rs1800871 5 -TCATTCTATGTGCTGGAGATGG-3 5 -TGGGGGAAGTGGGTAAGAGT-3-592A/C rs1800872 5 -GGTGAGCACTACCTGACTAGC-3 5 -CCTAGGTCACAGTGACGTGG-3 BseRI MsII RsaI G allele: 320 bp A allele: 360 bp, 320 bp T allele: 209 bp C allele: 93 bp, 116 bp A allele: 176 bp, 236 bp C allele: 412 bp Table 2. Demographic and clinical characteristics of esophageal cancer patients and control subjects Characteristics Patients % Controls % χ 2 test P value Sex Age Male 193 78.46 386 78.46 Female 53 21.54 106 21.54 0.00 1.00 <60 134 54.47 252 51.22 60 112 45.53 240 48.78 0.70 0.40 Smoking Never 105 42.68 250 50.81 Ever 141 57.32 242 49.19 4.34 0.04 Drinking Never 128 52.03 370 75.20 Ever 118 47.97 122 24.80 40.12 <0.001 Family history of cancer in the first relatives No 228 92.68 491 99.80 Yes 18 7.32 1 0.20 33.09 <0.001 Stage I-II 94 38.21 III-IV 152 61.79 matory cytokine, which could inhibit the synthesis of cytokines such as IL-6, IL-1β, IL-1α, and TNF-α in activated macrophage and IFNγ by T cells [9]. Several studies have reported that the IL-10 gene polymorphisms are associated with an increased risk of esophageal cancer [10-12]. Therefore, we conducted a hospital-based case-control study to investigate the association of three common SNPs (-1082G/A rs1800896, -819T/C rs1800871, and -592A/C rs1800872) of IL-10 gene polymorphisms with the susceptibility to esophageal cancer in a Chinese population. Materials and methods Study subjects Patients with pathologically proven esophageal cancer were recruited from the Second Affiliated Hospital of Zhengzhou University during the period between March 2011 and May 2014. All the cases were newly diagnosed and previously untreated. A total of 271 patients were collected from our hospital, and finally 246 patients agreed to participate into our study, with a participation rate of 90.78%. Clinical characteristics of esophageal cancer patients were obtained from medical records. 492 healthy control subjects free of a history of cancer were collected from health examination clinics in our hospital. Two control subjects matched with one patient in terms of age and gender. Cases and controls were interviewed using a standardized questionnaire including socio-demographic characteristics, including age, sex, tobacco smoking, alcohol drinking and family history of cancer in the first relatives. Detailed clinical data on cases were collected from medical records. 5 ml blood sample and signed informed consent form was obtained from every participant before their participation in the study. This protocol was approved by the Clinical Research Ethics Committee of the Second Affiliated Hospital of Zhengzhou University. Genotyping analysis Blood sample was collected in ethylenediamine tetra-acetic acid (EDTA) coated tubes and stored at -20 C until use. Genotyping of IL-10-1082G/A rs1800896, -819T/C rs1800871, and -592A/C rs1800872 was performed using the Sequenom MassARRAY platform (Sequenom; San Diego, CA). The primers used for polymerase chain reaction (PCR) were listed 9581 Int J Clin Exp Pathol 2015;8(8):9580-9585
Table 3. Association between IL-10-1082G/A rs1800896, -819T/C rs1800871, and -592A/C rs1800872 polymorphisms and risk of esophageal cancer IL-10 gene Patients % Controls % P for HWE OR (95% CI) 1 P value -1082G/A rs1800896 GG 99 40.24 242 49.19 1.0 (Ref.) GA 106 43.09 204 41.46 1.28 (0.90-1.80) 0.15 AA 41 16.67 46 9.35 0.74 2.19 (1.31-3.64) 0.001 GA+AA 147 59.76 250 50.81 1.44 (1.05-1.99) 0.02-819T/C rs1800871 TT 101 41.06 219 44.51 1.0 (Ref.) TC 105 42.68 203 41.26 1.12 (0.79-1.59) 0.50 CC 40 16.26 69 14.02 0.06 1.26 (0.77-2.03) 0.32 TC+CC 145 58.94 272 55.28 1.16 (0.84-1.60) 0.36-592A/C rs1800872 AA 85 34.55 185 37.60 1.0 (Ref.) AC 116 47.15 228 46.34 1.11 (0.78-1.58) 0.56 CC 45 18.29 79 16.06 0.53 1.24 (0.77-1.98) 0.35 AC+CC 161 65.45 307 62.40 1.14 (0.82-1.59) 0.42 1 Adjusted for age, sex, smoking, drinking and family history of cancer in the first relatives. Table 4. Stratification analysis of IL-10-1082G/A rs1800896 genotypes by demographic characteristics in esophageal cancer patients and controls Variables Smoking Patients Controls GG GA+AA GG GA+AA OR (95% CI) 1 P value Never 43 62 126 124 1.47 (0.90-2.39) 0.1 Ever 56 85 116 126 1.42 (0.91-2.22) 0.1 Drinking Never 53 75 182 188 1.37 (0.89-2.10) 0.13 Ever 46 72 60 62 1.57 (0.91-2.70) 0.09 Family history of cancer in the first relatives No 92 136 241 250 1.57 (0.91-2.70) 0.09 Yes 7 11 1 0 - - 1 Adjusted for age and sex. reactions were performed at 94 C for 30 s, 94 C for 5 s, followed by 40 cycles at 52 C for 5 s and 80 C for 5 s, with a final incubation at 72 C for 3 min. Purified extension reaction products with cation exchange resin were spotted onto Spectro CHIPs and measured by MALDI- TOF mass spectrometry. Statistical analyses in Supplementary Table 1. Multiplex PCR mixture contained 1 HotStar Taq buffer, 2.8 mm MgCl 2, 0.1 U of Hot Star Taq polymerase, 2 ng of genomic DNA, 0.5 pmol of each primer, and 0.5 mmol of dntps. Reaction was performed at 94 C for 15 min, followed by 45 cycles at 94 C for 20 s, 56 C for 30 s, and 72 C for 1 min, with a final incubation at 72 C for 3 min. Unincorporated dntps were deactivated using 0.3 U of shrimp alkaline phosphatase (SAP) followed by primer extension using 5.4 pmol of each extension probe, 50 mmol of iplex Termination Mix, and 0.5 U of iplex enzyme (Sequenom; San Diego, CA). The extension SPSS 16.0 statistical package (SPSS, Chicago, IL, USA) was taken to perform statistical analyses. The statistical difference between cases and controls was analyzed by A Chi-squared test and t test. The Hardy-Weinberg equilibrium (HWE) was tested by Fisher s exact test for each SNP in controls. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression analyses adjusted for age and gender, and the most common control homozygote was used as reference. Additional regression models were designed where subjects were stratified on smoking, drinking and family history of cancer subgroups 9582 Int J Clin Exp Pathol 2015;8(8):9580-9585
and genetic polymorphism carriers of the studied variations. All tests were two-sided with a significant level of P-value <0.05. Results The demographic and clinical characteristics of all the esophageal cancer cases and controls were shown in Table 2. No age and sex related differences were found between patients and controls (P>0.05). By comparing with control groups, esophageal cancer patients were more likely to have a habit of smoking and drinking, and have a family history of cancer in first relatives (P<0.05). Of 246 patients, 94 (38.21%) were at stage I-II, and 152 (61.79%) were at stage III-IV. The genotype distributions of IL-10-1082G/A rs1800896, -819T/C rs1800871, and -592A/C rs1800872 confirmed with HWE in the controls, and P values for HWE were 0.74, 0.06 and 0.53, respectively (Table 3). Unconditional logistic regression analyses showed that subjects carrying the AA genotype and GA+AA genotype of IL-10-1082G/A rs1800896 were associated with an increased risk of esophageal cancer, and the adjusted ORs (95% CI) were 2.19 (1.31-3.64) and 1.44 (1.05-1.99), respectively. However, we did not find significant association of IL-10-819T/C rs1800871 and -592A/ C rs1800872 with the development of esophageal cancer. By stratification analysis, we found that IL-10-1082G/A rs1800896 polymorphism has no significant association with smoking, drinking and family history of cancer in the first relatives in esophageal cancer risk (P>0.05) (Table 4). Discussion Genetic susceptibility to cancers has attracted a growing attention to investigate the gene polymorphisms in the tumourigenesis. Inflammation and related cytokines play a critical role in the epithelium transformation from precancerous lesion to esophageal cancer. The inflammatory state is a necessary step to maintain and promote cancer progression and complete the full malignant phenotype, including tumor tissue rebuilding, angiogenesis and metastasis and suppressing the innate anticancer immune response [13]. Genetic variations would promote cell transformation to cancer proliferation. IL-10 gene is an anti-inflammatory cytokine and mediates the T helper cell Th1/Th2 balance during the immune response [14]. The immunosuppressive effect of IL-10 gene inhibits cellmediated immune responses against cancer cells [15]. Our study has reported a significant association between IL-10-1082G/A rs180-0896 polymorphism and risk of esophageal cancer. Several studies have reported the role of IL-10-1082G/A gene polymorphism in the development of several kinds of cancers, such as cervical cancer, lung cancer, gastric cancer, colorectal cancer and digestive cancer [16-19]. Zhang et al. conducted a meta-analysis with eight studies, and reported that no significant association between IL-10 gene-1082g/a polymorphism and cervical cancer in any genetic models [16]. Hsia et al. evaluated the contribution of IL-10-1082G/A, -819T/C, and -592A/C genetic polymorphisms to the risk of lung cancer in Taiwan, and they reported that CC and TC genotypes of IL-10-819T/C had a protective effect on lung cancer risk [17]. Yu et al. explored the relation of IL-10-1082G/A gene polymorphism with gastric cancer risk, and they found that IL-10-1082G/A gene contributed to the susceptibility for gastric cancer [18]. A recent meta-analysis has investigated the association between IL-10-1082G/A gene polymorphisms and risk of digestive cancer, and it reported that IL-10-1082A>G polymorphism was only associated with increased risk for gastric cancer [19]. The discrepancies of the above mentioned results could be explained by differences in ethnicities, study design and tumor types as well as sample size. For the association between IL-10 gene polymorphisms and development of esophageal cancer, only three studies reported their association [10-12]. Savage et al. firstly conducted a study in a Chinese population, and they found that variations of IL-10 genes were not associated with esophageal cancer risk [10]. Guo et al. investigated the association of IL-10-1082G/ A gene polymorphism with susceptibility to esophageal cancer in 355 cancer patients and 443 controls, and they found that IL-10-G1082A polymorphism might not be associated with risk of esophageal cancer [11]. Sun et al. conducted a case-control study in a Chinese population, and found that IL-10-592A/C gene polymorphism contributed to esophageal cancer susceptibility [12]. However, we found that IL-10-1082A>G polymorphism could influence 9583 Int J Clin Exp Pathol 2015;8(8):9580-9585
the susceptibility for esophageal cancer in a Chinese population. Therefore, further studies with large sample size are greatly needed to confirm our results. Several limitations should be considered in our study. First, subject selection bias may overestimate the true size of effect or lead to spurious findings. Although there may exist selection bias for hospital-based subjects recruited in this study, both cases and controls were matched on age and sex, which may have minimized the bias. Second, we were not able to evaluate the gene-environment interactions, such as dietary factors. Third, we did not explore the genetic effects on the esophageal grade due to the limited sample size. Therefore, the actual biological mechanism of effects of IL-10 gene polymorphisms on esophageal cancers required further large-scale studies in different ethnic groups and functional experiments to replicate our findings. In conclusion, we observe that IL-10-1082G/A rs1800896 polymorphism contributes to the susceptibility for esophageal cancer, but IL-10-1082G/A rs1800896 has not interaction with smoking, drinking and family history of cancer in the risk of esophageal cancer. IL-10-1082G/A rs1800896 genetic variation may be employed as candidate biomarkers for the prediction of susceptibility in esophageal cancer. Disclosure of conflict of interest None. Address correspondence to: Dr. Xianen Fa, The Second Affiliated Hospital of Zhengzhou University, 2 Jingba Road, Zhengzhou, Henan, China. Tel: +86-371-63620625; Fax: +86-371-63620625; E-mail: xianenfa@163.com References [1] Internaltional Agency for Research on Cancer. Oesophageal Cancer. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/pages/fact_sheets_ cancer.aspx. 2012. Accessed in 2014-1-1. [2] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917. [3] Yaegashi Y, Onoda T, Morioka S, Hashimoto T, Takeshita T, Sakata K, Tamakoshi A. Joint effects of smoking and alcohol drinking on esophageal cancer mortality in Japanese men: findings from the Japan collaborative cohort study. Asian Pac J Cancer Prev 2014; 15: 1023-1029. [4] Tang WR, Chen ZJ, Lin K, Su M, Au WW. Development of esophageal cancer in Chaoshan region, China: association with environmental, genetic and cultural factors. Int J Hyg Environ Health 2015; 218: 12-18. [5] Zheng H, Zhao Y. Association of CYP1A1 MspI polymorphism in the esophageal cancer risk: a meta-analysis in the Chinese population. Eur J Med Res 2015; 20: 46. [6] Yun YX, Dai LP, Wang P, Wang KJ, Zhang JY, Xie W. Association of polymorphisms in X-ray repair cross complementing 1 gene and risk of esophageal squamous cell carcinoma in a Chinese population. Biomed Res Int 2015; 2015: 509215. [7] Li K, Yin X, Yang H, Yang J, Zhao J, Xu C, Xu H. Association of the genetic polymorphisms in XRCC6 and XRCC5 with the risk of ESCC in a high-incidence region of North China. Tumori 2015; 101: 24-29. [8] Cai Q, Wu J, Cai Q, Chen EZ, Jiang ZY. Association between Glu504Lys polymorphism of ALDH2 gene and cancer risk: a meta-analysis. PLoS One 2015; 10: e0117173. [9] D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gammaproduction by suppressing natural killer cell stimulatory factor/il-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-1048. [10] Savage SA, Abnet CC, Haque K, Mark SD, Qiao YL, Dong ZW, Dawsey SM, Taylor PR, Chanock SJ. Polymorphisms in interleukin-2, -6, and -10 are not associated with gastric cardia or esophageal cancer in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 2004; 13: 1547-1549. [11] Guo W, Wang N, Wang YM, Li Y, Wen DG, Chen ZF, He YT, Zhang JH. Interleukin-10-1082 promoter polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high-incidence region of north China. World J Gastroenterol 2005; 11: 858-862. [12] Sun JM, Li Q, Gu HY, Chen YJ, Wei JS, Zhu Q, Chen L. Interleukin 10 rs1800872 T>G polymorphism was associated with an increased risk of esophageal cancer in a Chinese population. Asian Pac J Cancer Prev 2013; 14: 3443-3447. [13] Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 2010; 10: 2-3. 9584 Int J Clin Exp Pathol 2015;8(8):9580-9585
[14] Saraiva M, O Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170-181. [15] Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274. [16] Zhang S, Kong YL, Li YL, Yin YW. Interleukin-10 gene-1082g/a polymorphism in cervical cancer and cervical intraepithelial neoplasia: meta-analysis. J Int Med Res 2014; 42: 1193-1201. [17] Hsia TC, Chang WS, Liang SJ, Chen WC, Tu CY, Chen HJ, Yang MD, Tsai CW, Hsu CM, Tsai CH, Bau DT. Interleukin-10 (IL-10) promoter genotypes are associated with lung cancer risk in Taiwan males and smokers. Anticancer Res 2014; 34: 7039-7044. [18] Yu T, Lu Q, Ou XL, Cao DZ, Yu Q. Clinical study on gastric cancer susceptibility genes IL-10-1082 and TNF-α. Genet Mol Res 2014; 13: 10909-10912. [19] Li C, Tong W, Liu B, Zhang A, Li F. The-1082A & gt; G polymorphism in promoter region of interleukin-10 and risk of digestive cancer: a metaanalysis. Sci Rep 2014; 4: 5335. 9585 Int J Clin Exp Pathol 2015;8(8):9580-9585